Lupin Partners with Huons for Dry Eye Treatment Launch in Mexico

Lupin has partnered with South Korean firm Huons to market a dry eye treatment medication in Mexico. The agreement includes the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion. This treatment aims to improve healthcare and eyecare solutions, expanding Lupin's presence in the ophthalmology market.

Drug maker Lupin announced on Thursday its collaboration with Huons Co Ltd, a South Korea-based pharmaceutical company, to market a dry eye treatment medication in Mexico.

Lupin has entered into a license and supply agreement with Huons for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion (0.4mL single-use vial) in Mexico, according to a statement from the Mumbai-based company.

Cyclosporine Ophthalmic Nanoemulsion, a preservative-free solution for dry eye syndrome and corneal ulcers, has already gained approval in South Korea, Peru, and various Middle Eastern countries.

'With this addition to our ophthalmology portfolio, we continue to strengthen our commitment to provide better healthcare and eyecare solutions to our patients, improving patient quality of life and vision,' said Fabrice Egros, President of Corporate Development and Growth Markets at Lupin.

Yohun Aum, Senior Director and Head of Global Business Division at Huons, noted that the product's introduction in Mexico marks a significant milestone. 'We look forward to strengthening our partnership by supplying high-quality products for Mexico,' Aum added.

(With inputs from agencies.)